



 C K

## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

### BIDDER'S UNDERTAKING FOR BID CUM APPLICATION FORM

**(IN CASE OF A JOINT APPLICATION, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)**

On the basis of the Red Herring Prospectus dated February 01, 2018 filed with the Registrar of Companies, Kerala and Lakshadweep at Kochi ("RHP"), the General Information Document for Investing in Public Issues ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Offer upto my/our Bids for maximum number of Equity Shares at or above the Offer Price, to be discovered through the Book Building Process. I/We hereby confirm that I am/We are eligible person(s) to invest in the Offer in accordance with applicable laws. I/We agree to accept the Equity Shares Bid for, or such lesser number as may be allotted to me/us subject to the terms of the RHP, Abridged Prospectus, the GID, the Bid cum Application Form and other applicable laws. The amount payable on bidding has been blocked with the relevant SCSB. I/We undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be allotted and to register my/our address as given in the depository records and to place my/our name on the register of members of the Company. I/We note that in case of QIB Bidders, (i) the SCSBs (for Bids other than Bids by Anchor Investors) and (ii) the GCBRLMs and the BRLMs and the Syndicate Member (only in the Specified Locations) have the right to reject Bids (including technical rejections) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, where as it has a right to reject it from Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP. I/We authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for registering of the Prospectus with the Registrar of Companies, Kerala and Lakshadweep at Kochi without intimation to me/us and use this Bid cum Application Form as the Application Form for the purpose of this Offer.

**I/WE CONFIRM THAT:** EITHER I am/We are Indian national(s) resident in India and I am/we are not applying for the said Equity Shares as nominees of any person resident outside India or foreign nationals OR I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity Shares as power of attorney holder(s) of Non-Resident Indian(s) as mentioned on Non-Repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity Shares on my/our own behalf through NRO account on Non Repatriation basis. I/We and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares confirm that I am/we are, or at any time the Equity Shares are purchased will be, the beneficial owner of such Equity Shares and I/we and any customer I/we represent, (A) I am/we are either (i) located outside the United States within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act") and are purchasing the Equity Shares in an "offshore transaction" in reliance on Regulation S under the Securities Act or (ii) are a "qualified institutional buyer" (as defined in Rule 144A under the Securities Act), (B) I/we have received a copy of the RHP (if we are in India) or the RHP and the accompanying preliminary international wrap (collectively, the "Preliminary Offering Memorandum") (if we are outside India) and that my/our investment decision is based solely on the RHP or the Preliminary Offering Memorandum, as applicable, (C) I/we have read and agree to the representations, warranties and agreements contained in the sections "Transfer Restrictions" and "Distribution and Solicitation Restrictions" of the Preliminary Offering Memorandum or the sections "Offer Information - Terms of the Offer" of the RHP, as applicable, and (D) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate. I am/We are and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares (A) understand that the Equity Shares are being offered in a transaction not involving any public offering in the United States, and (B) understand that the Equity Shares have not been and will not be registered under the Securities Act or under the securities laws of any state of the United States and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws.

Accordingly, the Equity Shares are only being offered and sold (i) in the United States only to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act, "Rule 144A") in reliance on the exemption from registration requirements of the Securities Act provided by Rule 144A, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

For details relating to the paid up equity share capital of the Company, see "Capital Structure" beginning on page 100 of the RHP.

**FOR QIB BIDDERS:** We confirm that the Bid size/maximum Equity Shares applied for by us do not exceed the relevant regulatory approvals/limits. I/We am/are not prohibited from accessing capital markets under any order/ruling/ judgment of any regulatory, judicial or any other authority, including SEBI or under the provisions of any law, regulation or statute.

**Further:** 1) In accordance with ASBA process provided in SEBI ICDR Regulations and as disclosed in the RHP, I/We authorise (a) the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centers) or the SCSBs or the RTAs or the CDPs as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading my/our Bid, blocking or unblocking of funds in the bank account maintained with the SCSB as specified in the Bid cum Application Form, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB shall reject the application. 3) I/We hereby authorise the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs or CDPs or the RTAs, as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band. **As per the existing policy of the Government of India, OCBs cannot participate in this Offer. For further details see "Offer Procedure" and "Restrictions on Foreign Ownership of Indian Securities" on pages 599 and 639 of RHP.**

### INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the depository account is held) should be provided in the Bid cum Application Form.
- The First Bidder, should mention his/ her PAN allotted under the Income Tax Act, except for Bids by or on behalf of the Central or State Government and the officials appointed by the Courts and by investors residing in the state of Sikkim, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the depository account is held), should mention his/ her PAN allotted under the Income Tax Act. Any Bid cum Application Form without the PAN is liable to be rejected.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar will obtain Demographic Details registered with Depository Participants to be used, among other things for Allotment or technical rejections or unblocking of ASBA Account. Hence, Bidders are advised to immediately update any change in their details as appearing on the records of the Depository Participant. Please note that failure to do so could result in failure in Allotment of Equity Shares, delay in unblocking of ASBA Account, at the Bidder's sole risk and neither the Syndicate or the Registered Brokers or the Registrar or RTAs/CDPs or the SCSBs nor the Company shall have any responsibility and undertake any liability for the same.
- Price Band and Bid Lot:** The Price Band and the minimum Bid Lot for the Offer will be decided by our Company and the Selling Shareholder in consultation with the BRLMs and will be advertised in all editions of The Financial Express, an English national newspaper, in all editions of Jansatta, a Hindi national newspaper, and in the Kochi edition of Mangalam, a Malayalam newspaper (Malayalam being the regional language of Kerala, where our Registered Office is located), each with wide circulation, at least five Working Days prior to the Bid/Offer Opening Date and shall be made available to the Stock Exchanges for the purpose of uploading on their websites. In case of revision of the Price Band, the Bid/Offer Period will be extended for at least three additional Working Days after revision of Price Band subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release and also by indicating the changes on the websites of the Managers and on the terminals of the Syndicate Members and by intimation to SCSBs, Registered Brokers, CDPs and RTAs.  
**Maximum and Minimum Bid Size:** In case of resident Retail Individual Bidders, bids must be such number of Equity Shares such that the Bid Amount does not exceed ₹ 200,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price, at the time of the submission of the Bid cum Application Form. **"Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted".** All NRI Bidders bidding on repatriation basis by using the Non-Resident forms are required to authorise their SCSB to block their NRE/ FCNR/ ASBA Accounts, and all NRI Bidders bidding on a non-repatriation basis by using Resident forms are required to authorise their SCSB to block their Non-Resident Ordinary (NRO) accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. The NRI Bidders can obtain the Bid cum Application Form from the Company's Registered Office or from any of the members of the Syndicate or CDPs or RTAs or Registered Brokers from their offices. Bidders to please ensure that your Bank has notified an SCSB Branch in the city where Bid cum Application Form is being submitted.
- Only the First Bidder is required to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder (necessary revisions in the Bidders undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares in proposed).
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms. c. Ensure that all applicable documents in support of the Bid are attached with the Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid Cum Application Form is liable to be rejected.

**Note:** Terms used but not defined herein shall have the meaning assigned to such terms in the RHP. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is available on the websites of the GCBRLMs, BRLMs and Stock Exchanges.

TEAR HERE

	COMPANY CONTACT DETAILS	REGISTRAR CONTACT DETAILS
<ul style="list-style-type: none"><li>In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Offer</li><li>In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB</li><li>In case of queries related to upload of Bids submitted to the Syndicate Members/RTAs/Registered Brokers/CDPs, as applicable the Bidders should contact the relevant Designated Intermediary.</li></ul>	<b>ASTER DM HEALTHCARE LIMITED</b> <b>Registered and Corporate Office:</b> IX/475L, Aster Medcity, Kuttisahib Road, near Kothad Bridge, South Chittoor P.O., Cheranallor, Kochi - 682 027, Ernakulam, Kerala, India <b>Contact Person:</b> Rajesh A., Company Secretary and Compliance Officer; <b>Tel:</b> +91 484 6699 228; <b>Fax:</b> +91 484 6699 862 <b>E-mail:</b> investors@asterdmhealthcare.com; <b>Website:</b> www.asterdmhealthcare.com <b>Corporate Identification Number:</b> U85110KL2008PLC021703	<b>LINK INTIME INDIA PRIVATE LIMITED</b> C-101,1st Floor, 247 Park, Lal Bahadur Shastri, Marg, Vikhroli (West), Mumbai - 400 083 Maharashtra, India <b>Tel:</b> +91 22 4918 6200, <b>Fax:</b> +91 22 4918 6195 <b>E-mail:</b> adhl ipo@linkintime.co.in <b>Investor grievance email:</b> adhl.ipo@linkintime.co.in <b>Website:</b> www.linkintime.co.in <b>Contact Person:</b> Shanti Gopalkrishnan <b>SEBI Registration No.:</b> INR000004058

This is an abridged prospectus containing salient features of the Red Herring Prospectus dated February 01, 2018 (the “RHP”).  
You are encouraged to read greater details available in the RHP.

**THIS DOCUMENT CONSISTS OF FOUR PAGES OF APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.**

Please ensure that you have read the RHP, this abridged prospectus and the General Information Document (“GID”) for investing in public offers undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of RHP/Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid-cum-Application Form and the RHP from Stock Exchanges (as defined below), members of the Syndicate, Registered Brokers, Collecting Depository Participants (“CDPs”), Registrar and Share Transfer Agents (“RTAs”), Registrar to the Offer, Underwriters, Bankers to the Offer and Self Certified Syndicate Banks (“SCSBs”). You may also download the RHP from the websites of the Securities and Exchange Board of India (“SEBI”), National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”) or the “Designated Stock Exchange” (collectively, “Stock Exchanges”) where the Equity Shares are proposed to be listed and the Global Co-Ordinators and Book Running Lead Managers (“GCBRLMs”) i.e. [www.investmentbank.kotak.com](http://www.investmentbank.kotak.com), [www.axiscapital.co.in](http://www.axiscapital.co.in), [www.goldmansachs.com](http://www.goldmansachs.com) and the Book Running Lead Managers (“BRLMs”) i.e. [www.icicisecurities.com](http://www.icicisecurities.com), [www.jmfl.com](http://www.jmfl.com), [www.yesinvest.in](http://www.yesinvest.in) respectively. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.



## ASTER DM HEALTHCARE LIMITED

Our Company was incorporated as DM Healthcare Private Limited on January 18, 2008 at Kochi, Ernakulam, Kerala as a private limited company under the Companies Act, 1956. The name of our Company was changed to Aster DM Healthcare Private Limited and a fresh certificate of incorporation consequent upon change of name was issued on November 29, 2013. Our Company was converted into a public limited company consequent to a special resolution passed by our Shareholders at the extraordinary general meeting held on November 10, 2014 and the name of our Company was changed to Aster DM Healthcare Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on January 1, 2015. For details of change in the name and registered office of our Company, see “History and Certain Corporate Matters” on page 197.

**Registered and Corporate Office:** IX/475L, Aster Medcity, Kuttisahib Road, near Kothad Bridge, South Chittoor P.O., Cheranalloor, Kochi - 682 027, Ernakulam, Kerala, India

**Contact Person:** Rajesh A., Company Secretary and Compliance Officer; **Tel:** +91 484 6699 228; **Fax:** +91 484 6699 862

**E-mail:** [investors@asterdmhealthcare.com](mailto:investors@asterdmhealthcare.com); **Website:** [www.asterdmhealthcare.com](http://www.asterdmhealthcare.com) **Corporate Identification Number:** U85110KL2008PLC021703

### OUR PROMOTERS: DR. AZAD MOOPEN AND UNION INVESTMENTS PRIVATE LIMITED

**PUBLIC OFFER OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH (“EQUITY SHARES”) OF ASTER DM HEALTHCARE LIMITED (“COMPANY” OR “ISSUER”) FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) AGGREGATING UP TO ₹[•] MILLION (“OFFER”) COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES AGGREGATING UP TO ₹7,250 MILLION (“FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 13,428,251 EQUITY SHARES BY OUR PROMOTER, UNION INVESTMENTS PRIVATE LIMITED (“UIPL” OR THE “SELLING SHAREHOLDER”) AGGREGATING UP TO ₹[•] MILLION (“OFFER FOR SALE”). THE OFFER WILL CONSTITUTE [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.**

**THE FACE VALUE OF THE EQUITY SHARES IS ₹10 EACH. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE SELLING SHAREHOLDER AND THE GLOBAL CO-ORDINATORS AND BOOK RUNNING LEAD MANAGERS (“GCBRLMs”) AND BOOK RUNNING LEAD MANAGERS (“BRLMs” AND TOGETHER WITH THE GCBRLMs, THE “MANAGERS”), AND WILL BE ADVERTISED IN ALL EDITIONS OF THE FINANCIAL EXPRESS, ALL EDITIONS OF JANSATTA AND KOCHI EDITION OF MANGALAM (WHICH ARE WIDELY CIRCULATED ENGLISH, HINDI AND MALAYALAM NEWSPAPERS, MALAYALAM BEING THE REGIONAL LANGUAGE OF KERALA, WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED) AT LEAST FIVE WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE BSE LIMITED (“BSE”) AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE”, AND TOGETHER WITH BSE, THE “STOCK EXCHANGES”) FOR THE PURPOSE OF UPLOADING ON THEIR WEBSITES.**

### PROCEDURE:

If you wish to know about processes and procedures applicable to public issues, you may request for a copy of the GID from the GCBRLMs & the BRLMs or download it from the websites of the NSE and BSE at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com), respectively and the GCBRLMs i.e. [www.investmentbank.kotak.com](http://www.investmentbank.kotak.com), [www.axiscapital.co.in](http://www.axiscapital.co.in), [www.goldmansachs.com](http://www.goldmansachs.com) and the BRLMs i.e. [www.icicisecurities.com](http://www.icicisecurities.com), [www.jmfl.com](http://www.jmfl.com), [www.yesinvest.in](http://www.yesinvest.in) respectively.

### ELIGIBILITY FOR THE OFFER – REGULATION 26(1) OF SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 (“SEBI ICDR REGULATIONS”)

Whether the Company is compulsorily required to allot at least 75% of the net Offer to Qualified Institutional Buyers –No

### INDICATIVE TIMELINE

Bid/Offer Opens Date	February 12, 2018	Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account	On or about February 22, 2018
Bid/Offer Closes Date	February 15, 2018	Credit of Equity Shares to demat accounts of Allottees	On or about February 23, 2018
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or about February 22, 2018	Commencement of trading of the Equity Shares on the Stock Exchanges	On or about February 26, 2018

### GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 17 of RHP.

**PRICE INFORMATION OF PAST ISSUES HANDLED BY THE GCBRLMS AND BRLMs**

Sr. No.	Issue Name	Name of Merchant Banker	+/- % change in closing price, [+/- % change in closing benchmark]- 30th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180th calendar days from listing
1	Newgen Software Technologies Limited	Isec	-	-	-
2	Future Supply Chain Solutions Limited	Yes	+4.09% [+3.85%]	-	-
3	Khadim India Limited	Axis	-10.40% [+0.06%]	-	-
4	The New India Assurance Company Limited	Kotak, Axis, Yes	-27.91% [+0.15%]	-	-
5	Mahindra Logistics Limited	Kotak, Axis	3.12% [-0.54%]	-	-
6	Reliance Nippon Life Asset Management Company Limited	Axis, JM, Yes	+3.61% [-3.19%]	-	-
7	General Insurance Corporation of India	Kotak, Axis	-12.92% [0.52%]	-13.95% [+6.52%]	-
8	Indian Energy Exchange Limited	Kotak, Axis	-8.15% [1.39%]	1.77% [+6.97%]	-
9	Godrej Agrovet Limited	Kotak, Axis	+14.96% [-0.43%]	+34.95% [+4.40%]	-
10	Prataap Snacks Limited	JM	+25.12% [+5.70%]	+31.82% [+5.60%]	-
11	SBI Life Insurance Company Limited	Kotak, Axis, JM, Isec	-7.56% [+5.89%]	-0.66% [+6.81%]	-
12	ICICI Lombard General Insurance Company Limited	JM, Isec	+3.62% [+6.25%]	+18.97% [+8.17%] +17.60% [+7.78%]	-
13	Matrimony.Com Limited	Axis, Isec	-12.28% [+0.62%]	-7.64% [+3.37%]	-
14	Dixon Technologies (India) Limited	Yes	+50.78% [+0.57%]	+98.26% [+2.32%]	-
15	Cochin Shipyard Limited	JM	+27.06% [+2.31%]	+30.96% [+6.10%]	-
16	Security and Intelligence Services (India) Limited	Kotak, Axis, Isec, Yes	-3.29% [+1.17%]	+3.14% [+5.40%]	-
17	AU Small Finance Bank Limited	Isec	+58.76% [+2.12%]	+65.20% [+2.23%]	+95.38% [+8.06%]
18	GTPL Hathway Limited	JM, Yes	-10.71% [+4.87%]	-19.09% [+1.82%]	-2.94% [+9.54%]
19	Central Depository Services (India) Limited	Axis, Yes	+127.92% [+5.84%]	+128.62% [+2.61%]	+139.03% [+10.19%]
20	Housing and Urban Development Corporation Limited	Isec	+13.17% [+2.44%]	+34.67% [+4.98%]	+35.67% [+8.05%]
21	S Chand And Company Limited	Axis, JM	-17.37% [+3.72%]	-25.38% [+8.05%]	-27.92% [+12.19%]
22	Healthcare Global Enterprises Limited	Kotak, GS	-15.32% [+1.45%]	-19.98% [+4.65%]	-1.31% [+14.17%]

Source: [www.nseindia.com](http://www.nseindia.com)

Notes:

1. Disclosure subject to recent 7 issues (Initial Public Offering) in current financial year and two preceding financial years.

2. In the event any day falls on a holiday, the price/index of the immediately preceding working day has been considered.

3. Nifty is considered as the benchmark index

For further details please refer to "Price information of past issues handled by Managers" beginning on page 581 of the RHP.

**Names of Global Co-ordinators and Book Running Lead Manager(s) and contact details (telephone and email id) of each Lead Manager**

<b>Kotak Mahindra Capital Company Limited</b> Tel: +91 22 4336 0000 E-mail: <a href="mailto:asterdmhealthcare ipo@kotak.com">asterdmhealthcare ipo@kotak.com</a> Investor grievance email: <a href="mailto:kmccredressal@kotak.com">kmccredressal@kotak.com</a>	<b>Axis Capital Limited</b> Tel: +91 22 4325 2183 E-mail: <a href="mailto:asterdmhealthcare ipo@axiscap.in">asterdmhealthcare ipo@axiscap.in</a> Investor grievance e-mail: <a href="mailto:complaints@axiscap.in">complaints@axiscap.in</a>	<b>Goldman Sachs (India) Securities Private Limited</b> Tel: +91 22 6616 9000 E-mail: <a href="mailto:gs-admh-ipo@gs.com">gs-admh-ipo@gs.com</a> Investor grievance email: <a href="mailto:india-client-support@gs.com">india-client-support@gs.com</a>
--	---	--

**Names of Book Running Lead Manager(s) and contact details (telephone and email id) of each Lead Manager**

<b>ICICI Securities Limited</b> Tel: +91 22 2288 2460 E-mail: <a href="mailto:asterdmhealthcare ipo@icicisecurities.com">asterdmhealthcare ipo@icicisecurities.com</a> Investor grievance email: <a href="mailto:customercare@icicisecurities.com">customercare@icicisecurities.com</a>	<b>JM Financial Limited*</b> Tel: +91 22 6630 3030 Email: <a href="mailto:admh.ipo@jmfml.com">admh.ipo@jmfml.com</a> Investor grievance email: <a href="mailto:grievance.ibd@jmfml.com">grievance.ibd@jmfml.com</a>	<b>YES Securities (India) Limited</b> Tel: +91 22 7100 9829 E-mail: <a href="mailto:dlasterdm.ipo@yessecuritiesltd.in">dlasterdm.ipo@yessecuritiesltd.in</a> Investor grievance e-mail: <a href="mailto:igc@yessecuritiesltd.in">igc@yessecuritiesltd.in</a>
--	--	---

\* JM Financial Limited has become a SEBI registered Category I Merchant Banker consequent upon amalgamation of JM Financial Institutional Securities Limited with it effective from January 18, 2018.

<b>Name of Registrar to the Offer and contact details (telephone and email id)</b>	<b>Link Intime India Private Limited</b> Tel: +91 22 4918 6200, E-mail: <a href="mailto:adh1.ipo@linkintime.co.in">adh1.ipo@linkintime.co.in</a> , Investor grievance email: <a href="mailto:adh1.ipo@linkintime.co.in">adh1.ipo@linkintime.co.in</a>
<b>Name of Syndicate Member</b>	Kotak Securities Limited, JM Financial Services Limited
<b>Statutory Auditors to the Company</b>	B S R and Associates, Chartered Accountants



## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

<b>Internal Auditors to the Company</b>	Grant Thornton India LLP.
<b>Self-Certified Syndicate Banks</b>	The list of banks that have been notified by SEBI to act as the SCSBs for the ASBA process is provided on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes">http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes</a> . For the list of branches of the SCSBs named by the respective SCSBs to receive the ASBA Forms from the Designated Intermediaries, please refer to the above-mentioned link.
<b>Registered Brokers</b>	The list of the Registered Brokers, including details such as postal address, telephone number and e-mail address, is provided on the websites of the Stock Exchanges at <a href="http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?expandable=3">http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?expandable=3</a> and <a href="http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm">http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm</a> , respectively, as updated from time to time.
<b>Details regarding website address(es)/ link(s) from which the investor can obtain list of Registrar to Offer and Share Transfer Agents, Depository Participants and stock brokers who can accept applications from investors, as applicable:</b>	List of RTAs, CDPs and Registered Brokers who are eligible to accept ASBA Forms from Investors can be obtained from below links as updated from time to time: RTAs and CDPs: As provided on the websites of NSE and BSE at <a href="http://www.nseindia.com/products/content/equities/ipo/asba_procedures.htm">www.nseindia.com/products/content/equities/ipo/asba_procedures.htm</a> and <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6">www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6</a> respectively, as updated from time to time. Registered Brokers: As provided on the websites of NSE and BSE at <a href="http://www.nseindia.com">www.nseindia.com</a> and <a href="http://www.bseindia.com">www.bseindia.com</a> , respectively, as updated from time to time. For further details, see section "Offer Procedure" beginning at page 599 of the RHP.

### PROMOTERS OF OUR COMPANY

Dr. Azad Moopen and UIPL are the Promoters of our Company. While Dr. Azad Moopen does not directly hold any Equity Shares in our Company, our corporate Promoter, UIPL currently holds 202,134,341 Equity Shares, equivalent to 43.28% of the pre-Offer issued, subscribed and paid-up Equity Share capital of our Company.

### BUSINESS MODEL/ BUSINESS OVERVIEW AND STRATEGY

**Overview:** We are one of the largest private healthcare service providers which operate in multiple GCC states based on numbers of hospitals and clinics, according to the Frost & Sullivan Report, and an emerging healthcare player in India. We currently operate in all of the GCC states, which comprise the United Arab Emirates, Oman, Saudi Arabia, Qatar, Kuwait and Bahrain, in Jordan (which we classify as a GCC state as part of our GCC operations), in India and the Philippines. Our GCC operations are headquartered in Dubai, United Arab Emirates and our Indian operations are headquartered in Kochi, Kerala.

**Key Strengths:** • Long standing presence across GCC states and India with strong brand equity; • Well diversified portfolio of service offerings to leverage multiple market opportunities; • Provision of high quality healthcare service • Ability to attract and retain high quality medical professionals; • Ability to identify, adapt to and capitalise on market developments, conditions, trends and opportunities; • Track record of operating and financial performance and growth • Experienced core management team.

**Strategy:** • Continue to grow within our existing centres; • Increase our presence by way of greenfield expansions • Pursue inorganic growth opportunities to expand into newer service offerings or new markets; • Capitalise on mandatory health insurance in GCC; • Implementation of initiatives to improve existing operational efficiencies and profitability.

### BOARD OF DIRECTORS

Sr. No.	Name	Designation	Experience including current / past position held in other firms
1.	<b>Dr. Azad Moopen</b>	Chairman and Managing Director	He is a gold medalist in Medicine and a post graduate in General Medicine from University of Calicut, Kerala, India and a diploma holder in Tuberculosis and Chest Diseases from Delhi University, Delhi, India. He has been honoured by the Government of India with the Padma Shri Award in 2011 and the Pravasi Bharatiya Samman in 2010.
2.	<b>T. J. Wilson</b>	Non-Executive Director*	He holds a bachelor's degree in Commerce from the University of Calicut, Kerala, India. He is also a member of the Institute of Chartered Accountants of India
3.	<b>Anoop Moopen</b>	Non-Executive Director	He holds a bachelor's degree in Civil Engineering from the University of Madras, Tamil Nadu, India and a master's degree in International Construction Management and Engineering from the University of Leeds, United Kingdom.
4.	<b>Alisha Moopen</b>	Non-Executive Director**	She holds a bachelor's degree in Business Administration from the University of Michigan, Ann Arbor. She is a member of the Institute of Chartered Accountants of Scotland. She has previously worked at Ernst and Young LLP.
5.	<b>Daniel Robert Mintz</b>	Non-Executive Director	He holds a master's degree in Business Administration from the Stanford Graduate School of Business Administration and a bachelor's degree in Arts in Political Science, magna cum laude and Phi Beta Kappa from Brown University.
6.	<b>Shamsudheen Bin Mohideen Mammu Haji</b>	Non-Executive Director	He has been a Director of our Company since September 16, 2015.
7.	<b>Harsh Charandas Mariwala</b>	Independent Director	He holds a bachelor's degree in Commerce from the University of Mumbai, India. He is the promoter of Marico Limited and Kaya Limited. He was ranked as one of India's best CEOs in the FMCG category (mid sized companies) by Business Today.

## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

8.	<b>Rajagopal Sukumar</b>	Independent Director	He holds a bachelor's degree in engineering from the Birla Institute of Technology and Science, Pilani, Rajasthan, India and completed an executive development program from the Wharton School of Business, University of Pennsylvania, USA.
9.	<b>Ravi Prasad</b>	Independent Director	He holds a bachelor's degree in Science from Ranchi University and a master's degree in business management from the Asian Institute of Management, Manila, Philippines. He has experience in the pharmaceutical industry.
10.	<b>Daniel James Snyder</b>	Independent Director	He holds a bachelor's degree in Science, Technical Careers (Health Care Services) from the Southern Illinois University, USA. He also holds a master's degree in Arts, from the Webster College Missouri, USA and a degree of Associate in Arts from the College of Dupage.
11.	<b>M. Madhavan Nambiar</b>	Independent Director	He holds a bachelor's degree in Arts from the University of Madras and has completed his master's in business administration from the University of Delhi.
12.	<b>Suresh M. Kumar</b>	Independent Director	He holds a bachelor's degree in Commerce from the University of Bombay.

\* Also, Executive Director and Group Head – Governance and Corporate Affairs, GCC

\*\* Also, Executive Director and CEO – Hospitals and Clinics, GCC

## OBJECTS OF THE OFFER

The Offer comprises the Fresh Issue and the Offer for Sale. For further details, see “Objects of the Offer” on page 115 of the RHP.

### Net Proceeds

The details of the proceeds of the Fresh Issue are summarised in the table below:

(₹ in million)

Particulars	Amount
Gross Proceeds	7,250
(Less) Fresh Issue related expenses <sup>(1)</sup>	[●]
<b>Net Proceeds</b>	<b>[●]</b>

(1) To be finalised upon determination of the Offer Price

### Schedule of Implementation and Deployment of Net Proceeds

The Net Proceeds are currently expected to be deployed in accordance with the schedule set forth below:

(In ₹ million)

Particulars	Total Estimated Cost	Amount which will be financed from Net Proceeds <sup>(1)</sup>	Estimated Utilisation of Net Proceeds		
			Fiscal 2018	Fiscal 2019	Fiscal 2020
Repayment and/or pre-payment of debt	5,641.56	5,641.56	5,641.56	-	-
Purchase of medical equipment	1,103.11	1,103.11	300.00	803.11	-
General corporate purposes <sup>(1)</sup>	[●]	[●]	[●]	[●]	[●]
<b>Total</b>	<b>[●]</b>	<b>[●]</b>	<b>[●]</b>	<b>[●]</b>	<b>[●]</b>

(1) To be finalised upon determination of Offer Price

### Shareholding Pattern

Sr. No.	Particulars	Pre Issue number of shares	% Holding of Pre Issue
1.	<b>Promoter &amp; Promoter Group</b>	202,134,341	43.28%
2.	<b>Public</b>	261,230,548	55.93%
3.	<b>Non Promoter-Non Public</b>	3,704,562	0.79%
	<b>Total</b>	467,069,451	100%

## RESTATED AUDITED FINANCIALS

### Consolidated

(₹ in million)

	As at 30 September 2017 Ind As	Fiscal 2017 Ind AS	Fiscal 2016 Ind AS	Fiscal 2015 Proforma Ind AS	Fiscal 2014 Previous GAAP	Fiscal 2013 Previous GAAP
Revenue from Operations	31,225.85	59,312.87	52,498.90	38,758.43	28,711.45	19,217.42
Profit / (Loss) before Taxation	(661.81)	2,885.34	376.29	3,062.61	3,102.87	1,508.55
Net Profit/(Loss) as Restated	(827.08)	2,667.47	82.11	2,721.07	1,777.83	917.81

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Equity Share Capital	4,032.22	4,032.22	4,030.52	3,886.38	3,745.31	1,248.44
Other Equity	14,098.18	14,721.89	165.65	10,957.62	5,360.09	6,544.86
Total Equity	18,130.40	18,754.11	4,196.17	14,844.00	9,105.40	7,793.30
Basic earnings / (Loss) per share (in ₹)	(1.65)	4.29	(1.35)	3.39	4.75	2.45
Diluted earnings / (Loss) per share (in ₹)	(1.65)	4.28	(1.35)	3.37	4.73	2.44
Return on net worth (%)	(4.22%)	10.59 %	(14.06%)	8.94 %	19.53%	11.78%
Net asset value per share (in ₹)	39.13	40.50	9.61	37.87	24.31	20.81

## Standalone

(₹ in million)

	As at 30 September 2017 Ind As	Fiscal 2017 Ind AS	Fiscal 2016 Ind AS	Fiscal 2015 Proforma Ind AS	Fiscal 2014 Previous GAAP	Fiscal 2013 Previous GAAP
Revenue from Operations	2,612.92	3,795.12	1,890.77	530.15	8.86	9.09
Profit / (Loss) before Taxation	(411.65)	467.06	(1,697.18)	(770.01)	720.39	18.50
Net Profit/(Loss) as Restated	(411.65)	467.06	(1,697.18)	(778.44)	704.03	18.50
Equity Share Capital	4,032.22	4,032.22	4,030.52	3,886.38	3,745.31	1,248.44
Other Equity	18,888.41	19,248.56	5,349.68	2,085.97	1,033.39	3,425.47
Total Equity	22,920.63	23,280.78	9,380.20	5,972.35	4,778.70	4,673.91
Basic earnings / (Loss) per share (in ₹)	(0.89)	1.01	(3.89)	(1.99)	1.88	0.05
Diluted earnings / (Loss) per share (in ₹)	(0.89)	1.01	(3.89)	(1.99)	1.87	0.05
Return on net worth (%)	(1.80%)	2.01 %	(18.09%)	(13.03%)	14.73 %	0.40 %
Net asset value per share (in ₹)	49.47	50.28	21.49	15.25	12.76	12.48

## INTERNAL RISKS FACTORS

1. Our ownership structure in most of the GCC states is subject to risks associated with foreign ownership restrictions and the shareholder arrangements with local shareholders might be violative of the local laws of the jurisdictions.
2. Certain licenses required to operate our businesses in the GCC may be held to contravene legal requirements.
3. Certain nominee arrangements lack certain provisions of a protective nature commonly used in similar structures, which may adversely affect our business.
4. Our revenue is highly dependent on our operations in the GCC states. Further, our results of operations are, and are expected to continue to be, significantly affected by foreign ownership restrictions, financial, economic and political developments in or affecting the GCC states.
5. Our performance depends on our ability to recruit and retain high quality doctors and other healthcare professionals, such as nurses, pharmacists and technicians.

## SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

- A. Total number of outstanding litigations against the Company and amount involved :

Sr. No.	Nature of Litigation	Number of Outstanding Cases	Aggregate Approximate Amount Involved ( in millions)
1.	Civil	4	0.31
2.	Tax	25	206.15
3.	Regulatory Notices**	8	NA*
4.	Medico Legal	5	6.55

\*Less than Rs.0.01 million

\*\* Includes notices received by CMCL in respect of Aster CMI Hospital which is being operated and managed by our Company

- B. Brief details of top 5 material outstanding litigations against the Company

Particulars	Litigation filed by	Current Status	Amount Involved
Antony Rejoy had filed a writ petition W.P. (C). No. 19635/2013 before the High Court of Kerala, challenging permissions granted to our Company for building Aster Medcity, Kochi. This petition was dismissed on January 15, 2015. Subsequently, Antony Rejoy filed a petition before the Kerala Lok Ayukta in this regard.	Antony Rejoy	Our Company has filed a writ petition bearing W.P. (C). No. 3410/2015 before the High Court of Kerala, Ernakulam against the Kerala Lok Ayukta and Antony Rejoy challenging the proceedings pending before the Kerala Lok Ayukta. The matter is still pending.	Not Quantifiable

## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

A notice dated April 28, 2016 has been issued by the Karnataka State Pollution Control Board ("Karnataka State PCB") to our Company as occupier of Aster CMI Hospital, Bengaluru in relation to failure to communicate to the Karnataka State PCB that the management of the hospital has been taken over by our Company from Cauvery Medical Centre Limited and was operating with a different bed strength. The notice also states, <i>inter alia</i> , that the segregation for storage of different wastes at the final waste storage area needs to be improved.	Karnataka State Pollution Control Board	Our Company has responded to the notice and the matter is still pending.	Not Quantifiable
Three notices dated April 29, 2017 have been issued to our Company by the Assistant Drugs Controller, stating that based on inspections conducted at our premises on October 20, 2016 they have noted certain irregularities including <i>inter-alia</i> , not maintaining carbon copies of sales bills, conducting sale of drugs without recording the drugs license numbers and names of manufacturers and that sales bills were found to be without the signature of competent persons. We have been asked to show cause as to why certain the drug licenses issued to our Company should not be suspended.	Assistant Drugs Controller	Our Company has replied to the notices and the matter is still pending.	
The United Nurses Association, Ernakulam District Committee has submitted a demand letter which has been received on June 30, 2017 by Aster Medcity, Kochi for <i>inter-alia</i> enhancement of monthly salary, within two weeks of the letter failing which, they have threatened to launch an indefinite strike.	United Nurses Association, Ernakulam District Committee	The matter is still pending.	Not Quantifiable
An assessment order has been passed disallowing the tax credit claimed by the Company under the provisions of Section 90/90A of the Income Tax Act, 1961 read with Article 23 of the India Mauritius Double Taxation Avoidance Agreement.	Deputy Commissioner of Income Tax, Corporate Circle – 1, Kochi	The Company has appealed before the Commissioner of Income Tax (Appeals) against the proceedings initiated by the Deputy Commissioner of Income Tax, Corporate Circle – 1, Kochi. The matter is pending.	Rs. 119,269,921

**C. There has been no disciplinary action taken by SEBI or stock exchanges against the Promoters / Group companies in last 5 financial years including outstanding action.**

**D. Criminal Proceedings against the Promoters**

1. A criminal petition C.M.P. No. 1184/2012 had been filed by P.G. Hari before the Enquiry Commissioner and Special Judge, Kozhikode against the Secretary, Department of Health and Dr. Azad Moopen alleging that the Secretary, Department of Health had abused her position as a public servant to obtain pecuniary advantage by forging documents and wrongly granting an essentiality certificate for the establishment of a medical college by DM Education and Foundation Trust and that she had entered into a criminal conspiracy to this effect with Dr. Azad Moopen. The matter is currently pending before the High Court of Kerala, Ernakulam.
2. Two separate complaints M.P. Nos. CC.928/15 and CC.929/15 have been filed by Treesa Joseph and Molly Antony before the Judicial First Class Magistrate Court – II, Ernakulam against DM Med City and others. Each complainant has alleged that she is the joint owner of 40 cents of property at Cheranalloor village. The complainants have alleged that the accused submitted a sale agreement with the High Court of Kerala, Ernakulam which was forged with the name of the respective complainants. Molly Antony has also sought the addition of Dr. Azad Moopen's name as the chairman of D M Medcity in this regard. The Judicial First Class Magistrate- II, Ernakulam, permitted the addition of the name of Dr. Azad Moopen as a respondent. Dr. Azad Moopen challenged the above orders and sought a stay against them. These matters are pending.

### ANY OTHER IMPORTANT INFORMATION AS PER BRLMs/COMPANY - NIL

#### DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act and the guidelines issued by the Government or the regulations, rules or guidelines issued by SEBI, established under Section 3 of the SEBI Act, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SEBI Act or rules or regulations made or guidelines issued thereunder, as the case may be. We further certify that all disclosures made in the Red Herring Prospectus are true and correct.

#### DECLARATION BY THE SELLING SHAREHOLDER

The undersigned Selling Shareholder hereby certifies that all statements and undertakings made by it in the Red Herring Prospectus solely and specifically in relation to itself and the Equity Shares being sold by it in the Offer for Sale are true and correct, provided however, it is specifically mentioned herein and agreed that the undersigned Selling Shareholder assumes no responsibility for any of the statements made by the Company or any expert or any other person(s) in the Red Herring Prospectus.



**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.**

**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.**

## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

### BIDDER'S UNDERTAKING FOR REVISION FORM

I/We (on behalf of joint bidders, if any) confirm that the Acknowledgement Slip for my/our bids are enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us.

I/We (on behalf of joint bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my existing Bids as appearing on the electronic book building system do not tally with the details given in this Revision Form.

### INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

1. Name of sole/ First Bidder should be exactly the same as it appears in the depository records.
2. Please ensure that the Bid Options provided are in the same order as that provided in the Bid Cum Application Form submitted earlier.
3. In case there is no change in the particular Bid Option, please write "NO CHANGE". In case you want to cancel the Bid Option, please write "CANCELLED".
4. Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total amount to be paid must be calculated net of total amount paid at the time of submission of Bid Cum Application Form. Bidders, please ensure that your Bank has notified an SCSB Branch in the city where Bid-cum-Application Form is being submitted. Revision of Bids in case of Revision of Price Band: In case of an upward revision in the Price Band, Retail Individual Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment does not exceed ₹ 200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 200,000 the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. (i) In case of a downward revision in the Price Band, announced as above, Retail Individual Bidders who has bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
5. Only the First Bidder is required to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA account holder. Signature of the ASBA Account holder is mandatory.
6. **Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Syndicate Member/ SCSBs/Collecting Agents/Registered Brokers/RTAs/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgement Slip for your Bid has and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount, in excess of their original blocked amount, based on the cap of the revised Price Band upon an upward revision of their Bid.

### OFFER STRUCTURE

Number of Equity Shares available for Allotment/ allocation <sup>*(2)</sup>	Up to [●] Equity Shares or issue less allocation to Non-Institutional Bidders and Retail Individual Bidders	Not less than [●] Equity Shares available for allocation or Offer less allocation to QIB Bidders and Retail Individual Bidders	Not less than [●] Equity Shares available for allocation or Offer less allocation to QIB Bidders and Non-Institutional Bidders
Percentage of Offer Size available for Allotment/ allocation	50% of the Offer Size shall be available for allocation to QIBs. However, up to 5% of the net QIB Portion (excluding the Anchor Investor Portion) will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining net QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be available for allocation to QIBs	Not less than 15% of the Offer	Not less than 35% of the Offer
Basis of Allotment/ allocation if respective category is oversubscribed*	Proportionate as follows (excluding the Anchor Investor Portion): (a) [●] Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; and (b) [●] Equity Shares shall be Allotted on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above	Proportionate	The Allotment to each Retail Individual Investor shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares if any, shall be allotted on a proportionate basis. For details see, "Offer Procedure – Part B – Allotment Procedure and Basis of Allotment – Allotment to RIBs" on page 630
Mode of Bidding	ASBA only <sup>(1)</sup>	ASBA only	ASBA only
Minimum Bid	Such number of Equity Shares that the Bid Amount exceeds ₹200,000 and in multiples of [●] Equity Shares thereafter	Such number of Equity Shares that the Bid Amount exceeds ₹200,000 and in multiples of [●] Equity Shares thereafter	[●] Equity Shares and in multiples of [●] Equity Shares thereafter
Maximum Bid	Such number of Equity Shares not exceeding the size of the Offer, subject to applicable limits	Such number of Equity Shares not exceeding the size of the Offer, subject to applicable limits	Such number of Equity Shares so that the Bid Amount does not exceed ₹200,000
Mode of Allotment	Compulsorily in dematerialized form	Compulsorily in dematerialized form	Compulsorily in dematerialized form
Bid Lot	[●] Equity Shares and in multiples of [●] Equity Shares thereafter		
Allotment Lot	[●] Equity Shares and in multiples of [●] Equity Share thereafter		
Trading Lot	One Equity Share		
Who can apply	Public financial institutions as specified in Section 2(72) of the Companies Act, 2013, scheduled commercial banks, mutual funds, FPIs other than Category III Foreign Portfolio Investors, VCFs, AIFs, FVCIs registered with SEBI, multilateral and bilateral development financial institutions, state industrial development corporation, insurance company registered with IRDAI, provident fund (subject to applicable law) with minimum corpus of ₹250 million, pension fund with minimum corpus of ₹250 million, in accordance with applicable law and National Investment Fund set up by the Government of India, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically important NBFCs	Resident Indian individuals, Eligible NRIs, HUFs (in the name of Karta), companies, corporate bodies, scientific institutions, societies and trusts, Category III Foreign Portfolio Investors	Resident Indian individuals, Eligible NRIs and HUFs (in the name of Karta)
Terms of Payment	Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder that is specified in the ASBA Form at the time of submission of the ASBA Form <sup>(3)</sup>		

<sup>\*</sup>Assuming full subscription in the Offer

- (1) Our Company may, in consultation with the Selling Shareholder and the Managers allocate up to 60% of the QIB Category to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. QIB portion will be adjusted for the shares allocated to Anchor Investors. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being made to other Anchor Investors. For details, see "Offer Procedure" on page 599
- (2) Subject to valid Bids being received at or above the Offer Price, this Offer is being made in accordance with Rule 19(2)(b)/(iii) of the SCRR and under the SEBI ICDR Regulations
- (3) Anchor Investors are not permitted to use the ASBA process. Entire Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Form to the members of the Syndicate. For details of terms of payment applicable to Anchor Investors, please see section entitled "Offer Procedure – Part B - Section 7: Allotment Procedure and Basis of Allotment" on page 630

**COMMON BID  
REVISION FORM**

**ASTER DM HEALTHCARE LIMITED - INITIAL PUBLIC OFFER - R**  
 Registered and Corporate Office: IX/475L, Aster Medcity, Kuttisahib Road, near Kothad Bridge, South Chittoor P.O., Cheranalloor, Kochi - 682 027,  
 Ernakulam, Kerala, India Contact Person: Rajesh A., Company Secretary and Compliance Officer; Tel: +91 484 6699 228; Fax: +91 484 6699 862  
 E-mail: investors@asterdmhealthcare.com Website: www.asterdmhealthcare.com  
 Corporate Identification Number: U85110RT2008PTC021703

**FOR RESIDENT INDIANS, INCLUDING  
RESIDENT QIBs AND ELIGIBLE NRIs  
APPLYING ON A NON-REPATRIATION BASIS**



TO,  
THE BOARD OF DIRECTORS  
ASTER DM HEALTHCARE LIMITED

**100% BOOK BUILT OFFER**  
**ISIN: INE914M01019**

**Bid cum  
Application  
Form No.**

MEMBER OF SYNDICATE STAMP & CODE	REGISTERED BROKER/SCSB/CDP/RTA STAMP & CODE	1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER
		Mr. / Ms./M/s. _____ Address _____ Email _____ Tel. No (with STD code) / Mobile _____
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE	2. PAN OF SOLE / FIRST BIDDER
		_____
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.	3. BIDDER'S DEPOSITORY ACCOUNT DETAILS <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL
		For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

**PLEASE CHANGE MY BID**

4. FROM (AS PER LAST BID OR REVISION)													
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹)/ "Cut-off" (Price in multiples of ₹ 1/- only)				
	(In Figures)								(In Figures)				
	8	7	6	5	4	3	2	1	Bid Price	Retail Discount	Net Price	"Cut-off" (Please✓tick)	
Option 1												<input type="checkbox"/>	
(OR) Option 2												<input type="checkbox"/>	
(OR) Option 3												<input type="checkbox"/>	
5. TO (Revised Bid) (Only Retail Individual Bidders can Bid at "Cut-off")													
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹)/ "Cut-off" (Price in multiples of ₹ 1/- only)				
	(In Figures)								(In Figures)				
	8	7	6	5	4	3	2	1	Bid Price	Retail Discount	Net Price	"Cut-off" (Please✓tick)	
Option 1												<input type="checkbox"/>	
(OR) Option 2												<input type="checkbox"/>	
(OR) Option 3												<input type="checkbox"/>	

6. PAYMENT DETAILS										PAYMENT OPTION : FULL PAYMENT <input type="checkbox"/> PART PAYMENT <input checked="" type="checkbox"/>	
Additional Amount Blocked (₹ in figures) _____ (₹ in words) _____											
ASBA											
Bank A/c No. _____											
Bank Name & Branch _____											

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM AND THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUES ("GID") AND HEREBY AGREE AND CONFIRM THE 'BIDDERS UNDERTAKING' AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM GIVEN OVERLEAF.

7A. SIGNATURE OF SOLE/ FIRST BIDDER	7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)	MEMBER OF SYNDICATE / REGISTERED BROKER/ SCSB / CDP / RTA STAMP (Acknowledging upload of Bid in Stock Exchange system)
Date : _____ 2018	I/We authorise the SCSB to do all acts as are necessary to make the Application in the Offer. 1) _____ 2) _____ 3) _____	

TEAR HERE



**ASTER DM HEALTHCARE LIMITED**  
**BID REVISION FORM- INITIAL PUBLIC OFFER - R**

Acknowledgement Slip  
for MEMBER OF  
SYNDICATE/REGISTERED  
BROKER/SCSB/CDP/RTA

**Bid cum  
Application  
Form No.**

DPID / CLID	PAN of Sole / First Bidder										
Additional Amount Blocked (₹)					ASBA Bank A/c No.					Stamp & Signature of SCSB Branch	
Bank & Branch											
Received from Mr./Ms./M/s. _____											
Telephone / Mobile					Email						

TEAR HERE

ASTER DM HEALTHCARE  
LIMITED  
BID REVISION FORM - R  
INITIAL PUBLIC OFFER - R

	Option 1	Option 2	Option 3	Stamp & Signature of MEMBER OF SYNDICATE/ REGISTERED BROKER/ SCSB / CDP / RTA
No. of Equity Shares				
Bid Price				
Additional Amount Blocked (₹)				
ASBA Bank A/c No.				
Bank & Branch				

Name of Sole / First Bidder

Acknowledgement Slip for Bidder

**Bid cum  
Application  
Form No.**

TEAR HERE

PLEASE FILL IN BLOCK LETTERS

TEAR HERE

